TSHA: SEC Form 424B5 filed by Taysha Gene Therapies Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for TSHA
Across the 17 sessions after earlier TSHA headlines, the stock closed higher 12 times and lower 5 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TSHA | SPY |
|---|---|---|---|
| Jun 25, 2026 | Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | -10.5% | +0.1% |
| Jun 22, 2026 | Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome | +1.7% | -0.3% |
| Jun 5, 2026 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -6.6% | -2.6% |
| May 6, 2026 | Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | +0.6% | +1.4% |
| May 4, 2026 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +4.9% | -0.4% |
| Apr 29, 2026 | Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 | -0.5% | -0.0% |
Quantisnow market dataNASDAQ
TSHA
Taysha Gene Therapies Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for TSHA
Full TSHA profile on Quantisnow Follow TSHA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time